The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
Open accessAbstract
Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in animal models of neurodegenerative disorders. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson's disease (PD), and a clinical trial in PD patients showed promising first results. Liraglutide and lixisenatide are two newer GLP-1 mimetics which have a longer biological half-life than exendin-4. We previously showed that these drugs have neuroprotective properties in an animal model of Alzheimer's disease. Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p. When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen. Both liraglutide and lixisenatide showed effects in preventing the MPTP-induced motor impairment (Rotarod, open-field locomotion, catalepsy test), reduction in tyrosine hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia, a reduction of the pro-apoptotic signaling molecule BAX and an increase in the anti-apoptotic signaling molecule B-cell lymphoma-2. The results demonstrate that in this study, both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regarding Parkinson disease, earlier GLP-1RAs, such as liraglutide and lixisenatide, have been shown to protect dopaminergic neurons and reduce motor disability in animal models.32”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [32]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Researchers have discovered that GLP-1RAs exhibit a noticeable increase in the level of phosphorylated ERK1/2 within the sciatic nerve of diabetic rats.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [401]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Self-citationInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
McClean, P. L., & Hölscher, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 362
Self-citationEntry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V. L. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 358
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Gerlach, M., Riederer, P. F., Przuntek, H., & Youdim, M. B. H. (1991) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(91)90073-q · Cited by 307
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 303
Self-citationMotor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Avilés-Olmos, I., Dickson, J. C., Kefalopoulou, Z. M., Djamshidian, A., Kahan, J., Ell, P. J., Whitton, P. S., Wyse, R. K. H., Isaacs, T., Lees, A. J., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140364 · Cited by 300
Harkavyi, A., Abuirmeileh, A. N., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 294
MPTP Toxicity: Implications for Research in Parkinson's Disease
Kopin, I. J., & Markey, S. P. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000501 · Cited by 291
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263
Bondolfi, L., Calhoun, M., Ermini, F., Kuhn, H. G., Wiederhold, K.-H., Walker, L., Staufenbiel, M., & Jucker, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00515.2002 · Cited by 213
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Self-citationSharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Self-citationSmith, T. S., & Bennett, J. P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00429-0 · Cited by 129
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120
A New Alzheimers Disease Interventive Strategy: GLP-1
Perry, T. R., & Greig, N. H. (2004) · Current Drug Targets · doi:10.2174/1389450043345245 · Cited by 110
Parkinson’s Disease: Current and Future Challenges
Langston, J. W. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00098-0 · Cited by 109
Briyal, S., Shah, S. Z., & Gulati, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.064 · Cited by 105
Hölscher, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140016 · Cited by 97
Self-citationRaun, K., von Voss, P., & Knudsen, L. B. (2007) · Obesity · doi:10.1038/oby.2007.204 · Cited by 93
Takahashi, K., Funata, N., Ikuta, F., & Sato, S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-11 · Cited by 80
Kinemuchi, H., Fowler, C. J., & Tipton, K. F. (1987) · Neurochemistry International · doi:10.1016/0197-0186(87)90024-6 · Cited by 75
Gut hormones as therapeutic agents in treatment of diabetes and obesity
Tan, T., & Bloom, S. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.005 · Cited by 57
Nakamura, S., & Vincent, S. R. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90282-x · Cited by 54
Hakon, J., Ruscher, K., Romner, B., & Tomasevic, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120074 · Cited by 52
Ohtake, N., Saito, M., Eto, M., & Seki, K. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.04.003 · Cited by 46
Hölscher, C. (2014) · PubMed · Cited by 46
Self-citationThe role of MAO in MPTP toxicity--a review.
Glover, V. A. S., Gibb, C., & Sandler, M. B. (1986) · PubMed · Cited by 39
Lixisenatide: First Global Approval
Elkinson, S., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0033-3 · Cited by 37
GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
Mickiewicz, A. L., & Kordower, J. H. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247876 · Cited by 27
GLP‐1 improves neuropathology after murine cold lesion brain trauma
DellaValle, B., Hempel, C., Johansen, F. F., & Kurtzhals, J. A. L. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.99 · Cited by 26
Cited by
Sorted by citations
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
The Role of Autophagy in Parkinson's DiseasePreprint
Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., & Klionsky, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009357 · Cited by 477
Metadata
- Authors
- Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C.
- Affiliations
- Shanxi Medical University (CN)
- Lancaster University (GB)
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 303
- Pages
- 42-50
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2211963426
- Cited by
- 246
- References
- 38
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 32 · 2023: 15 · 2022: 33 · 2021: 20 · 2020: 16 · 2019: 17 · 2018: 27 · 2017: 11 · 2016: 16 · 2015: 7
- FWCI
- 14.33
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.lancs.ac.uk
- Locations
- Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- Funders
- Cure Parkinson’s Trust, UK
- Shanxi Province Government, China
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, liraglutide, lixisenatide, GLP-1 receptor agonists, neuroprotection, MPTP mouse model, exendin-4, dopamine synthesis, substantia nigra, Bax, Bcl-2, apoptosis, motor impairment, catalepsy
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Liraglutide, Exenatide, Animals, Basal Ganglia, Catalepsy, Disease Models, Animal, Male, Mice, Inbred C57BL, Motor Activity, Peptides, Substantia Nigra, Tyrosine 3-Monooxygenase, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Apoptosis, Neuroprotective Agents, Parkinsonian Disorders, Rotarod Performance Test, Mice, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
